---

Introduction: COVID 19 pandemic caused by SARS-COV2 virus has taken a toll all over the world. The susceptibility of various diseases like Helicobacter Pylori, Hepatitis B virus and Norwalk Virus and even SARS Corona Virus 1 have been associated with ABO blood groups. However, very limited data is available regarding the COVID 19 susceptibility and ABO blood groups. Methods: In the present report we investigated 500 admitted patients who were RTPCR positive for corona virus. Significant Tests were applied to study association of blood groups vis a vis disease severity, ICU admissions and assisted ventilation. Results:  We found out that Type A blood group is more susceptible to severe COVID 19 infection, even though maximum patients were of type B blood group. We also found that type A blood group needed more ICU admission and assisted ventilation then non type A groups and difference was statistically significant. Conclusion: Patients with type A blood group COVID 19 patients with type A blood group might require more vigilant surveillance and aggressive treatment measures. Further studies are required to validate the disease susceptibility.

---

Background and objectives: The outbreak of coronavirus disease 2019 (COVID-19) has become a global health emergency. The severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) NSP13 helicase plays an important role in SARS-CoV-2 replication and could serve as a target for the development of antivirals. The objective of the study was to perform homology modeling and docking analysis of SARS-CoV-2 NSP13 helicase as a drug target.

Methods: The structure and function of SARS-CoV-2 NSP13 helicase were predicted by in-silico modeling studies. The SWISS-MODEL structure assessment tool was used for homology modeling and visual analysis of the crystal structure of the protein. The validation for structure models was performed using PROCHECK. Model quality was estimated based on the QMEAN and ProSA. The MCULE-1-Click docking and InterEvDock-2.0 server were used for protein-ligand docking.
Results: The SARS-CoV-2 NSP13 helicase model corresponded to probability confirmation with 90.9% residue of the core section, which highlights the accuracy of the predicted model. ProSA Z-score of -9.17 indicated the good quality of the model. Inhibitor N-(3-(carbamoylamino) phenyl) acetamide exhibited effective binding affinity against the NSP13 helicase. The docking results revealed that Lys-146, Leu-147, Ile-151, Tyr-185, Lys-195, Tyr-224, Val-226, Leu-227, Ser-229 residues exhibit good binding interactions with inhibitor ligand N-(3-(carbamoyl amino) phenyl) acetamide.
Conclusion: Hence, the proposed inhibitor could potently inhibit SARS-CoV-2 NSP13 helicase, which is thought to play key roles during viral replication. The results of this study indicate that N-(3-(carbamoylamino) phenyl) acetamide could be a valuable lead molecule with great potential for SARS-CoV-2 NSP13 helicase inhibition.

---

Background and objectives: In coronavirus disease 2019 (COVID-19), elevated serum levels of C-reactive protein (CRP), a marker of systemic inflammation, are commonly observed. We aimed to investigate the associations between CRP test results and clinical characteristics in patients with COVID-19.
Method: In this cross-sectional study, data from 399 patients with COVID-19 were collected through a census method. The patients were divided into a CRP-positive group (n=335) and a CRP-negative group (n=64). Demographical data, laboratory findings, clinical characteristics, and history of some underlying diseases were compared between the two groups. All analyses were carried out in SPSS (version 21).
Results: The frequency of hypertension was 40.1% among the study population, 42.4 % among CRP-positive patients, and 28.1% among CRP-negative patients. Diabetes and heart disease were the most common comorbidities among the patients. Dyspnea (60.4%), fever (52.7%), fatigue (45.4%), and dry cough (40.1%) were the most commonly observed symptoms. The mean duration of hospitalization was 8.14±6.18 days, and the mean duration of intensive care unit stay was 9.09±9.41 days. Moreover, CRP positivity was significantly associated with hypertension, immunosuppressive therapy, and higher duration of hospitalization (p<0.05).
Conclusion: Pre-existing hypertension, diabetes, and heart disease with the coincidence of some clinical symptoms are associated with higher levels of CRP in COVID-19 patients, which results in longer hospitalization.

---

Background and objectives: This study aimed to study the interaction between the severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) spike protein complex and seven drugs that inhibit the angiotensin-converting enzyme 2.
Methods: Plots of protein-ligand interaction were obtained using the LigPlot software. In addition, binding energies in kcal/mol, hydrophobic interactions, and hydrogen bonds were determined. Autodock software v.1.5.6 and AutoDock Vina were used for the analysis of molecular docking processes.
Results: The only structure that interacted with the SARS‑CoV‑2 spike protein was anakinra.
Conclusion: Anakinra was the only drug that interacted with the SARS‑CoV‑2 spike protein. This could be further investigated for finding a temporary alternative medicine for the treatment of coronavirus disease 2019.

---

Background: COVID-19 is a viral infection caused by SARS-CoV-2, which enters the body via the ACE2 receptor. This study aims to evaluate the coagulation disorders of COVID-19 patients admitted to Centre Hospitalier Mère-Enfant Monkole, Kinshasa.
Methods: This descriptive cross-sectional hospital-based study of patient files was conducted between July 2020 and June 2021 at CHME-Monkole in Kinshasa. The sample size was 130 patients using a random sampling technique after interviewing the respondents. For each respondent, biological and socio-demographic data were collected on a questionnaire. The primary analyses included the determination of PT, APTT, Plasma determination of D-dimers, and platelet count. A descriptive analysis was performed for socio-demographic characteristics, while Pearson correlation was used to determine the associations between socio-demographic characteristics and different biological parameters using SPSS 25.0. For ethical reasons, informed consent from patients was sought, and confidentiality was assured. The authorization was provided by the Ethical Committee of CHME-Monkole (Ethical code: KIN/CHME/04/2020).
Results: The findings showed D-dimer levels higher than 500 µg/L in 87.7% of respondents, prolonged APTT (>40 seconds) in 43.1% of respondents, PT (<70%) in 36.9% of respondents, and thrombocytopenia (platelets <150,000) in 26.2% of respondents. A positive correlation was observed between socio-demographic characteristics and D-dimer levels.
Conclusion: SARS-CoV-2 infection has a significant impact on coagulation. Thus, determining these biomarkers could predict the risk of disease severity or death in patients with COVID-19.

---

Background: The complete blood count (CBC) profile has been found extremely useful in monitoring the growth of SARS-CoV-2 infection; however, predictive CBC parameters that could be used in the management of the disease may vary in different populations.
Methods: This study comparatively analyzed the CBC profile of SARS-CoV-2 patients (N = 75; confirmed positive by real-time polymerase chain reaction [PCR]) and healthy individuals (confirmed negative by real-time PCR) from Kashmir (north India).
Results: Compared with healthy individuals, most of the CBC parameters (hemoglobin levels [13.43 vs 10.9 g/dL; P = 0.0001], lymphocytes [16.04% vs 30.8%; P = 0.00001], monocytes [5.53% vs 7.53%; P = 0.009], and platelet count [150 vs 186 ×103 µL; P = 0.037]) were significantly low in SARS-CoV-2 infected patients, while neutrophilia was more common in infected patients (76.77% vs 59.26%). Among derived parameters, the neutrophil-to-lymphocyte ratio (NLR; 7.31 vs 2.04; P = 0.001) and derived NLR (d-NLR; 4.43 vs 1.5; P = 0.0002) were significantly high in SARS-CoV-2 patients. Further correlation analysis revealed a significant association of neutrophilia with the severity of the disease in SARS-CoV-2 infected patients. Moreover, receiver operating characteristic (ROC) analysis of derived CBC parameters (NLR, d-NLR, and platelet‐to-lymphocyte ratio [PLR] with disease severity and disease outcome) revealed d-NLR as better predictive marker of disease severity (area under the curve [AUC] = 0.658) and disease outcome (AUC = 0.766) compared to PLR with disease severity (AUC = 0.645) and disease outcome (AUC = 0.693).
Conclusion: We therefore conclude, of the CBC parameters neutrophilia as the marker of disease severity and among derived parameters, d-NLR as an early predictive biomarker of both disease severity and poor disease outcome in SARS-CoV-2 patients.